US shares: Is their phenomenal run done?

The S&P 500 Index has increased by 28.1% in the year to date. Can this extraordinary run continue?

Piggy bank on US flag with stock market data.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

US shares have had an amazing run in 2024 and have outperformed the S&P/ASX 200 Index (ASX: XJO).

In the year to date, the S&P 500 Index (SP: INX) has ascended 28.1%, and the Nasdaq Composite Index (NASDAQ: IXIC) has risen 33.4%.

Over the same period, the ASX 200 has increased by 10.7% (this excludes dividend returns).

Can the US markets continue to shine in 2025 after such a strong surge this year? And how will Donald Trump's election as US President change things for shares investors?

Let's canvas a few expert opinions on what's ahead for the US share markets in 2025.

US shares to return 10% in 2025, says Goldman Sachs

Top broker Goldman Sachs forecasts the S&P 500 to return 10% in 2025.

Goldman's research team predicts the S&P 500 will rise to 6,500 points by the end of 2025.

The index closed at 6,075.11 points overnight, down 0.19%. During intraday trade, the US benchmark index smashed another all-time high at 6,094.55 points.

David Kostin, chief US equity strategist at Goldman Sachs Research, predicts the S&P 500 will have a third consecutive year of gains amid solid economic expansion and earnings growth of 11% in 2025.

Kostin said the impact of Trump's tariffs and corporate tax cuts on Goldman's earnings per share (EPS) forecasts "roughly offset one another". The broker forecasts S&P 500 EPS of $268 per share in 2025.

But there are risks.

Kostin notes that the S&P 500's price-to-earnings (P/E) multiple has increased by 25% to 21.7x over the past two years, compared to 17x at the end of 2022.

Kostin comments:

An equity market that is already pricing an optimistic macro backdrop and carrying high valuations creates risks heading into 2025.

Higher multiples can lead to weaker near-term returns and magnify the effects of any downturn, he said.

Diversification away from the Magnificent Seven

JP Morgan Global Market Strategist Ian Hui said the Magnificent Seven has fuelled the rise of the S&P 500 in 2024 due to projected earnings growth of 36.2% compared to 3.1% for the rest of the index.

The Magnificent Seven US shares are Meta Platforms Inc (NASDAQ: META), Amazon.com, Inc. (NASDAQ: AMZN), Apple Inc (NASDAQ: AAPL), Alphabet Inc (NASDAQ: GOOGL) (NASDAQ: GOOG), Nvidia Corp (NASDAQ: NVDA), Microsoft Corp (NASDAQ: MSFT), and Tesla Inc (NASDAQ: TSLA).

Hui said:

Over the past two years, the seven mega-cap tech or tech-related companies have been major drivers of the U.S. equity market.

However, the focus isn't solely on their earnings. These companies are heavily investing in AI and research & development, suggesting the tech sector and tech-related companies will likely stay prominent.

According to JP Morgan's 2025 Market Outlook, the broker's base case for 2025 is a steadily expanding global economy, which should benefit risk assets like shares.

Hui notes early signs of investors diversifying away from the Magnificent Seven:

The contribution of the seven mega-cap tech-related companies to S&P 500 earnings per share (EPS) growth is decreasing, and their earnings growth rate is slowing, while it is accelerating for the rest of the index.

Hui said the rest of the S&P 500 should play a bigger role next year.

The rate-cutting cycle and resolution of election-related uncertainties should support a cyclical recovery in areas such as manufacturing, allowing less-favored sectors to benefit from tech-driven growth. This should help reduce concentration and valuation risks at the index level.

'Structural shifts' at play, says fund manager

Global fund manager Blackrock says it remains "risk-on" in today's non-typical business cycle amid significant long-term structural shifts.

In its Global 2025 Outlook, Blackrock says:

Mega forces like AI are transforming economies, breaking historical trends.

We stay risk-on as we look for transformation beneficiaries – and go further overweight U.S. stocks as the AI theme broadens out.

Blackrock does not think "pricey U.S. equity valuations alone will trigger a near-term reassessment".

However, the fund manager says it is "ready to adjust if markets become overexuberant".

US shares valuations stretched but 'justified'

Morgan Stanley also recommends going overweight in US shares (and Japanese equities).

In a recent research note, the broker said that US shares valuations were stretched but justified.

What justifies valuations that are richer than average, though, is a set of fundamentals that are better than average.

Markets have grown more certain that the U.S. economy and company fundamentals are sound, and this could send valuations yet higher six months from now if investors see that those fundamentals are sustained.

In a separate article, Morgan Stanley noted that US shares rallied after Trump's election. However, market exuberance has now settled, with investors focused on policy uncertainty heading into 2025.

Investors should consider reducing outsized holdings in the Magnificent 7 and other "Trump trade" outperformers.

Policy shifts are likely to produce new market leaders in 2025, and stock picking will be critical.

The broker favours US shares in financials, energy, residential real estate, domestically focused industrials, and branded consumer goods manufacturers.

Short-term view: Are we in a Santa Rally?

IG Australia Market Analyst Tony Sycamore says historical seasonality indicates further gains are likely for US shares through to mid-January.

Sycamore says:

Historically, the last two weeks of December rank as the third-best two-week period of the year, averaging a +0.99% return.

The first two weeks of January are even more positive, boasting an average return of 1.61%.

Together, they create the most favourable four-week stretch of the year, with an average return of 2.6%.

JPMorgan Chase is an advertising partner of Motley Fool Money. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Alphabet, Amazon, Apple, Goldman Sachs Group, JPMorgan Chase, Meta Platforms, Microsoft, Nvidia, and Tesla. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool Australia has recommended Alphabet, Amazon, Apple, Meta Platforms, Microsoft, and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Share Market News

Forget Westpac shares, these ASX ETFs could be better buys

Here's why these funds could be quality picks for investors looking for alternatives to the banks.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors.

Read more »

Rising real estate share price.
REITs

Macquarie names its top 4 ASX REITs to buy today

Macquarie expects these four dividend paying ASX REITs will all surge higher in 2026.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
Broker Notes

Why this ASX AI stock could return 40% in 2026

Let's see which stock Bell Potter is tipping to rise strongly.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Share Market News

Analysts name 2 top ASX 200 shares to buy today

Leading investment experts name two quality ASX 200 shares to buy now.

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Broker Notes

This ASX 200 gold stock has surged 77% in 2025. Here's why Macquarie expects it to leap another 23%

Macquarie forecasts 23% upside for this surging ASX gold stock, and that doesn’t include the dividends!

Read more »